Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Why Dialysis Stocks Plunged Today


Shares of several major dialysis stocks plunged on Wednesday after Novo Nordisk (NYSE: NVO) indicated one of its diabetes treatments could also be used to treat chronic kidney disease.

Dialysis products and services providers were broadly negative in early trading, including drops of around 19% each as of 12:00 p.m. EDT for DaVita (NYSE: DVA), Outset Medical (NASDAQ: OM), and Fresenius Medical (NYSE: FMS). Novo Nordisk stock was up around 4% on the news.

In a press release issued after the market closed yesterday, Novo Nordisk announced the decision to stop its kidney outcomes trial FLOW nearly a year earlier than expected. The FLOW trial began in 2019 and was studying the effect of a once-weekly dose of semaglutide versus a placebo in on the progression of renal impairment in 3,500 people with type 2 diabetes and chronic kidney disease. 

Continue reading


Source Fool.com

Fresenius SE & Co. KGaA Stock

€27.33
0.070%
With only a change of €0.020 (0.070%) the Fresenius SE & Co. KGaA price is nearly unchanged from yesterday.

Like: 0
NVO
Share

Comments